Drug Profile
Methylphenidate controlled release - Purdue Pharma
Alternative Names: Adhansia XR; Aptensio XR; Biphentin Capsules; FOQUEST; Methylphenidate ER; Methylphenidate extended release; PRC-063Latest Information Update: 05 Apr 2023
Price :
$50
*
At a glance
- Originator Purdue Pharma
- Developer Purdue Pharma; Rhodes Pharmaceuticals; Universite Laval
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors; Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
- Phase II Cognition disorders
Most Recent Events
- 01 Jul 2021 US FDA approves sNDA application for Methylphenidate controlled release (Adhansia XR®) to update the prescribing information for Attention deficit hyperactivity disorder
- 14 Jun 2021 Updated efficacy and adverse events data from a phase III trial in Attention-deficit hyperactivity disorder released by Adlon Therapeutics
- 18 Nov 2020 Efficacy and adverse events data from a phase II trial in Attention-Deficit/Hyperactivity Disorder (ADHD) released by Adlon Therapeutics